SlowBull
The Business Brief MONDAY, 31 AUGUST 2026
← All stories
Deals

Lilly adds to immune drug pipeline with $2.9B Merida buyout

1 source ·1 article ·2h ago

The big drugmaker’s latest company acquisition this year is centered around a technology designed to degrade proteins that malfunction in autoimmune disorders.

Covered by 1 outlet

Biopharmadive 1

All coverage · 1 article

BioPharma Dive ·2h ago

Lilly adds to immune drug pipeline with $2.9B Merida buyout

The big drugmaker’s latest company acquisition this year is centered around a technology designed to degrade proteins that malfunction in autoimmune disorders.